Metronidazole Topical Cream 75% (actual active ingredient is 0.75% metronidazole) is a topical antibacterial drug mainly used to treat diseases related to skin inflammation and bacterial infections, especially rosacea (rosacea). Its core ingredient is metronidazole, with a concentration of 0.75% (i.e. 7.5 milligrams of metronidazole per gram of cream). The drug exists in the form of a cream, with excipients including benzyl alcohol, emulsified wax, glycerol, isopropyl palmitate, purified water, sorbitol solution, lactic acid, and sodium hydroxide (used to adjust pH). In addition, metronidazole topical preparations also include 1% cream, 1% gel and 0.75% lotion, but 0.75% cream is one of the commonly used formulations. This cream is mainly used to treat inflammatory papules and pustules. The core symptoms of rosacea include erythema, papules, and pustules in the center of the face (nose, cheeks, chin). Topical metronidazole preparations can significantly reduce the number and severity of these inflammatory lesions. Some studies have shown that metronidazole also has a certain improvement effect on the persistent erythema of rosacea, but the efficacy may be weaker than that of papules and pustules.
|
|
|
Metronidazole Topical Cream 75% "destabilization" attack on bacterial networks
Rosacea, as a chronic inflammatory skin disease, has core pathological features including facial erythema, papules, pustules, and telangiectasia. In severe cases, it can lead to impaired skin barrier function and psychological and social burden. Traditional treatment relies on oral antibiotics (such as tetracyclines) or topical retinoids, but long-term use may cause dysbiosis, drug resistance, and systemic side effects. Metronidazole Topical Cream 75% is a nitroimidazole antibiotic, and its 0.75% topical cream has been on the market since the 1980s. With its unique antibacterial anti-inflammatory dual action mechanism, it has become a first-line drug for the treatment of rosacea.
Dynamic balance of bacterial network: the invisible driving force behind the onset of rosacea
Symbiosis and competition of skin microbiota
More than 1000 microorganisms are colonized on the surface of healthy skin, forming a dynamic equilibrium network centered around Staphylococcus, Propionibacterium, and Demodex. In patients with rosacea, this balance is disrupted: the proportion of S. epidermidis decreases, while S. aureus and D. folliculorum proliferate excessively. This dysbiosis exacerbates inflammation through the following mechanisms:
Metabolite stimulation: Alpha and delta toxins secreted by S. aureus can directly damage keratinocytes and induce the release of pro-inflammatory factors such as IL-6 and TNF - α;
Biofilm formation: The biofilm carried on the surface of D. folliculorum provides a colonization site for S. aureus, forming a "mite microbe co pathogenic unit";
Immune escape: The dysregulated microbiota weakens the innate immune defense of the skin by downregulating the expression of antimicrobial peptides such as LL-37.
Bacterial network stability and disease progression
The stability of bacterial networks depends on inter species interactions (such as competition, mutual benefit) and host immune regulation. In patients with rosacea, this stability is doubly disrupted:
External factors: UV irradiation, high temperature environment, and spicy diet induce skin oxidative stress and reduce microbial diversity;
Endogenous factors: Th1/Th17 immune shift leads to abnormal secretion of antimicrobial peptides, further weakening the inhibition of opportunistic pathogens.
Clinical data shows that the alpha diversity index (Shannon index) of facial microbiota in patients with rosacea is reduced by 30% -40% compared to healthy individuals, and the co-occurrence rate of S. aureus and D. folliculorum is as high as 72%, significantly higher than the 15% in healthy individuals. The formation of this "pathogenic bacteria alliance" makes it difficult for a single antibacterial treatment to be effective, and requires the use of a "destabilization" strategy to disrupt its synergistic relationship.
The "destabilization" mechanism of metronidazole cream: multi-target attack on bacterial networks
Direct antibacterial effect: nitro reduction dependent oxidative stress
The antibacterial activity of metronidazole depends on the reduction reaction of its nitro (- NO ₂) group in anaerobic environment:
Reduction pathway: In S. aureus and D. folliculorum, nitroreductase reduces metronidazole to nitroso radicals (· NO ₂) and hydroxylamine (NH ₂ OH), which induce bacterial death by disrupting the DNA double stranded structure and protein thiol groups;
Selective pressure: Compared to healthy skin microbiota such as S. epidermidis, S. aureus and D. folliculorum have 2-3 times higher levels of nitroreductase expression, making them more sensitive to metronidazole.
Clinical studies have shown that after 12 weeks of treatment with 0.75% metronidazole cream, the facial S. aureus load of patients decreased from 10 ⁵ CFU/cm ² to 10 ² CFU/cm ², while there was no significant change in S. epidermidis load, reflecting its selective antibacterial properties.
Indirect antibacterial effect: disrupting the symbiotic relationship between mites and bacteria
D. As a key pathogenic factor of rosacea, folliculorum enhances the survival of mites through the following mechanisms of S. aureus colonization in its body:
Nutritional supply: S. aureus breaks down triglycerides in sebum to provide free fatty acids for mites;
Immune masking: The S. aureus antigen in the biofilm on the surface of mites can interfere with host immune recognition.
Metronidazole disrupts this symbiotic relationship through a dual pathway:
Efficiency leap Precision and stability
Mite inhibition: directly acting on the mitochondria of D. folliculorum, inhibiting its energy metabolism, resulting in a 60% increase in mite mortality rate;
Microbial reconstruction: After reducing the load of S. aureus, the biofilm thickness on the surface of mites decreased from 50 μ m to 10 μ m, weakening their shielding effect on host immunity.
Anti inflammatory effect: blocking the cascade of inflammatory signals
The anti-inflammatory effect of metronidazole is independent of its antibacterial activity and is achieved through the following mechanisms:
Free radical scavenging: Neutralizes superoxide anions (O ₂⁻) and hydrogen peroxide (H ₂ O ₂), reducing oxidative stress damage to the skin;
Immune regulation: Inhibiting the Toll like receptor 2 (TLR2) - mediated NF - κ B signaling pathway and reducing the expression of pro-inflammatory factors such as IL-8 and IL-12;
Efficiency leap Precision and stability
Barrier repair: Upregulate the expression of filaggrin (FLG) and laminin (LOR) in keratinocytes to enhance skin barrier function.
A randomized controlled trial involving 200 patients showed that after 8 weeks of treatment with Metronidazole Topical Cream 75%, patients' transcutaneous water loss (TEWL) values decreased from 15 g/(m ² · h) to 10 g/(m ² · h), approaching the level of healthy individuals (8 g/(m ² · h)).
The "destabilization" strategy in clinical applications: optimizing efficacy and safety
Precision of dosage and treatment course
+
-
The efficacy and dosage of metronidazole cream exhibit a non-linear relationship:
Concentration selection: 0.75% concentration achieves a balance between antibacterial activity and irritability. Although 1% cream has stronger antibacterial properties, the incidence of local irritation (12%) is significantly higher than that of the 0.75% group (5%);
Course optimization: The initial treatment should last for 12 weeks to fully disrupt the stability of the bacterial network. Maintenance treatment can be reduced to 2-3 times per week, and the recurrence rate is reduced by 40% compared to the discontinuation group.
Synergistic effects of combination therapy
+
-
Metronidazole is often used in combination with other drugs to enhance the "destabilization" effect:
Combined with benzoyl peroxide (BPO): BPO destroys bacterial biofilms through strong oxidation, but may oxidize the nitro groups of metronidazole. Clinical recommendations include using BPO in the morning and metronidazole in the evening to avoid direct contact;
Combined with azelaic acid: azelaic acid reduces erythema by inhibiting tyrosinase activity, while lowering skin pH (4.5-5.5) and enhancing metronidazole solubility. After 12 weeks of combined use, the improvement rate of inflammatory skin lesions increased by 22% compared to using metronidazole alone.
Individualized adjustment for special populations
+
-
Pregnancy medication: Metronidazole can penetrate the placental barrier, but the systemic absorption rate of topical preparations is less than 1%. The FDA classifies it as a Class B pregnancy medication. It is recommended to use only when it is clearly necessary, and cream (rather than gel) is preferred to reduce irritation;
Patients with liver and kidney dysfunction: Patients with liver dysfunction need to reduce the dosage by half (0.375% cream, once daily) to avoid drug accumulation and neurotoxicity (such as peripheral neuropathy).
Challenge and Future Direction: From "De stabilization" to "Rebalance"
Although metronidazole has a low resistance rate (<5%), long-term use may still induce mutations in the nitroreductase gene. In the future, drug resistance can be delayed through the following strategies:
Pulse based administration: Adopting a cycle of "medication for 2 weeks - discontinuation for 1 week" to reduce sustained selection pressure;
Nano delivery system: Develop liposomes or microspheres loaded with metronidazole to achieve targeted release and reduce systemic exposure.
Simply 'de stabilizing' may damage the skin ecology, and in the future, it is necessary to combine probiotics (such as S. epidermidis) or prebiotics (such as bacterial lysates) to rebuild a healthy microbiota. A preliminary study showed that after 12 weeks of treatment with metronidazole combined with S. epidermidis lysate, the Shannon index of bacterial diversity in patients recovered to 85% of the level of healthy individuals, while the group treated with metronidazole alone only recovered to 60%.
Regarding the non selective oxidative stress damage of 75% in Metronidazole Topical Cream, safer derivatives can be developed through chemical modification
Reduced dependence on nitro reduction: Introducing electron donor groups (such as amino groups) to the imidazole ring reduces the redox potential required for nitro reduction;
Targeted delivery: Using antibody drug conjugate (ADC) technology, metronidazole is accurately delivered to S. aureus or D. folliculorum, reducing damage to host cells.
Hot Tags: metronidazole topical cream 75%, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale